Wall Street News Alert Issues Special Alert on BOCX! January 10, 2008
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding.
Highlighted Links
Our Home Page
FREE Email Alert Service
WESTON, FL--(Marketwire - January 10, 2008) - Wall Street News Alert's "stocks to watch" this morning are: BioCurex (OTCBB: BOCX), CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT), IDGLOBAL (PINKSHEETS: IDGJ) and Apollo Group, Inc. (NASDAQ: APOL).
BioCurex (OTCBB: BOCX) continues to issue positive news this week, and investors are urged to keep watching the company this morning. Yesterday after the markets closed, the biotechnology company with patented/proprietary technology identifying a cancer marker, RECAF, and Inverness Medical Innovations announced a licensing agreement for BioCurex's RECAF™ material and technology.
This should be great news for the company, as the press release states that more than three years of testing by BioCurex has confirmed RECAF's high degree of clinical sensitivity and specificity in detecting various types of cancer, even when the disease is at its earliest stage. RECAF (the receptor for alpha-fetoprotein) is a wide-spectrum marker present in malignant cancer cells and absent in most normal cells, allowing it to play a major role in the development of new diagnostic tests for prostate, breast, colorectal, lung and other cancers.
Under terms of the license agreement, Inverness Medical Innovations will obtain semi-exclusive worldwide rights to commercialize products using this technology. BioCurex will be paid up-front fees, product and development milestones, plus royalties on product sales.
According to the World Health Organization, more than 10 million people are diagnosed with cancer every year, and this number is expected to reach 15 million in a dozen years. The RECAF technology becomes hugely significant when considering that the chance of a cure increases substantially if the disease is detected early (i.e. the five-year survival rate for breast cancer ranges from 87% at Stage 1 to only 13% at Stage IV). Cancer screening and recurrent evaluations are anticipated diagnostic applications for the RECAF cancer marker.
Wall Street News Alert is alerting investors to monitor the progress of the BioCurex! "BioCurex's RECAF technology has the potential to revolutionize cancer detection by differentiating malignant cells from healthy ones. For this reason, we are delighted to be partnering with one of the world's leading developer/manufacturers of advanced diagnostic products. With major facilities in the U.S., Europe and Asia, Inverness Medical Innovations has an impressive reputation for aggressive and innovative consumer marketing. We are especially looking forward to working with them on expanding and implementing our RECAF technology on future cancer tests,'' said Ricardo Moro, M.D., BioCurex's CEO.
Prior to the latest press release, the stock closed Wednesday at Seventy cents a share.
To view all of Wall Street News Alert's special early morning trading alerts for this morning, visit www.WallStreetNewsAlert.com, where you may also sign up to receive free email alerts in advance of our press releases being issued.
In case you are not familiar with the companies: BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology for cancer diagnosis and therapy. The core technology identifies a cancer marker known as RECAF, found only on malignant cells in a variety of cancers, but absent in normal and most benign cells. BioCurex is also working on further methods for cancer detection and cancer treatment.
By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health.
AI
